Janux Therapeutics, Inc. (JANX) Stock
5 of the hedge funds AlphaScala tracks reported JANX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $30.63M.
Which hedge funds own JANX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 1.99M | $30.63M | +72% |
| Citadel Ken Griffin | 1.20M | $18.44M | +241% |
| D.E. Shaw David Shaw | 1.10M | $16.84M | +1014% |
| Millennium Management Israel Englander | 505K | $7.75M | +30% |
| Marshall Wace | 33K | $502.8K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →JANX price chart
Powered by TradingViewWhat does Janux Therapeutics, Inc. do?
Janux Therapeutics Inc. is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies for cancer and autoimmune diseases. It pioneers next-generation T cell engagers using proprietary TRACTr, TRACIr, and ARM platforms to create drug candidates that selectively activate immune responses in tumors, minimizing systemic safety issues and overcoming limitations of traditional immunotherapies. Key clinical programs include JANX007, a PSMA-targeted TRACTr in Phase 1 trials for metastatic castration-resistant prostate cancer and other tumors, and JANX008, an EGFR-targeted therapy in Phase 1 for solid tumors such as colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company maintains a strategic research collaboration with Merck Sharp & Dohme Corp. to advance TRACTr candidates. Focused on oncology and immunology, Janux Therapeutics Inc. aims to deliver safe, effective treatments that guide the immune system against disease. Incorporated in 2017 and headquartered in San Diego, California, it operates at the forefront of immunotherapy innovation.